Dimerix Limited · ASX:DXB
Dimerix — Technical Presentation (October 2026)
17 slides from Dimerix's technical presentation, Oct 23, 2026
Slide 1: New Human Data Strengthens Biological Rationale for DMX-200 in FSGS
For Immediate Release NEW HUMAN DATA STRENGTHENS BIOLOGICAL RATIONALE FOR DMX-200 IN FSGS For personal use only Highlights • New data presented at Kidney Week 2026 provides additional biological evidence supporting the inflammatory mechanism of action of DMX-200 which targets CCR2 1 in FSGS 2 • Inde
Slide 2: Biological Plausibility for DMX-200
The study identified elevated activation of the MCP-1/CCR2 inflammatory signalling pathway in patients with FSGS, and demonstrated associations between CCR2 pathway activation, kidney function decline and disease progression. Importantly, the findings support the scientific rationale for targeting C
Slide 3: ACTION3 Phase 3 status and potential catalysts
dose was stable, patients were randomised to receive either DMX-200 (120 mg capsule twice daily) or placebo. The ACTION3 adult cohort is fully recruited with 333 patients randomised and dosed globally. Recruitment has been completed across 219 sites in 21 countries including the United States, Europ
Slide 4: About Dimerix and DMX-200 in FSGS
patients as possible worldwide while creating long-term value for shareholders. For more information, please visit the company’s website at www.dimerix.com. About DMX-200 in FSGS FSGS is a rare, serious kidney disorder characterised by progressive scarring (sclerosis) in parts of the glomeruli - the
Slide 5: References
References 1 CCR2 (C-C chemokine receptor type 2, also known as CD192 or MCP-1 receptor) is a protein-coding G protein- coupled receptor (GPCR) 2 Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease characterised by scarring (sclerosis) in parts of some of the kidney's tiny filtering u
Slide 6: Intrarenal CCL2 and CCR2 Activation Profiles Linked to Urinary Biomarkers in FSGS
rsonal use only Intrarenal CCL2 and CCR2 Activation Profiles Are Linked to Noninvasive Urinary Biomarkers Associated with Outcomes in Patients with FSGS Sean Eddy, PhD University of Michigan Khun Zaw Latt, Carl White, John Hartman, Viji Nair, Phillip J. McCown, Virginia Vega-Warner, Yuee Wang, Wenju
Slide 7: CCL2-CCR2 axis
CCL2-CCR2 axis rsonal use only • Chemokine (C-C motif) ligand 2 (CCL2, also known as monocyte chemoattractant protein 1 (MCP-1)) activates chemokine (C-C motif) receptor 2 (CCR2) on monocytes/macrophages • CCR2 activation promotes cell migration, adhesion and macrophage chemotaxis • Attracts immune
Slide 8: NEPTUNE study network
NEPTUNE provides a collaborative, investigational infrastructure across 32 North American sites for translational NEPphrotic syndrome research in: sTUdy NEtwork • Focal Segmental Glomerulosclerosis (FSGS) rsonal use only • Minimal Change Disease (MCD) Precision Medicine for • • Membranous Nephropath
Slide 9: Demographics of patients with FSGS in NEPTUNE
Demographics of patients with FSGS in NEPTUNE rsonal use only NEPTUNE enrolled With RNAseq With snRNAseq Demographics (n=261) (n=118) (n=33) Age (mean ± SD, yrs) 34 ± 21 34 ± 21 34 ± 22 Female (%) 42 37 42 eGFR (mean ± SD, 70 ± 34 72 ± 31 64 ± 36 mL/min/1.73m2, CKD-Epi) UPCR (median [IQR], mg/mg) 3.
Slide 10: Developing CCR2 transcriptional gene activity network
Developing CCR2 transcriptional gene activity network in patients with FSGS rsonal use only • Differential expression of gene profiles from CCR2(+) compared to CCR2(-) CCR2 expression in immune cells and fibroblasts of snRNAseq profiles(immune patients with FSGS cells and fibroblasts) https://neptun
Slide 11: Developing CCR2 transcriptional gene activity network
Developing CCR2 transcriptional gene activity network in patients with FSGS rsonal use only • Differential expression of gene profiles UMAP of CCR2+ cells (blue) from CCR2(+) compared to CCR2(-) immune cells and fibroblasts of patients with FSGS • CCR2 co-expression analysis from tubulointerstitial
Slide 12: TI CCR2 TA was elevated and negatively correlated with eGFR
TI CCR2 TA was elevated in patients with FSGS and negatively correlated with eGFR rsonal use only ✱✱✱✱ 3 3 2 2 CCR2 TA score CCR2 TA score 1 1 0 0 R=-0.5 -1 p<0.0001 -1 -2 -2 2 4 6 8 Living donor FSGS Log2 eGFR, CKD-Epi Similar associations were observed in the microdissected glomerular compartment
Slide 13: Could a urine MCP-1 biomarker profile serve as a surrogate of CCR2 activation?
Could a urine MCP-1 biomarker profile serve as a non- invasive surrogate of CCR2 activation in the kidney? rsonal use only CCR2 Downstream Gαi Gβ signaling cascades MCP-1 and transcriptional (CCL2) activity (including MCP-1) CCR2 TA score
Slide 14: uMCP-1/Cr associated with composite endpoint
uMCP-1/Cr was associated with a composite endpoint (40% loss of eGFR or ESRK) in patients with FSGS rsonal use only Probability of Kidney Survival 100 50 uMCP-1/Cr high uMCP-1/Cr low Log rank p=0.04 0 0 500 1000 1500 2000 2500 Days elapsed
Slide 15: Conclusions
Conclusions rsonal use only • A transcriptional profile associated with CCR2 activation was elevated in patients with FSGS and associated with a urine biomarker profile of MCP-1 • The urine profile was associated with a composite kidney endpoint in patients with FSGS • Taken together, these results
Slide 16: Acknowledgements
Acknowledgements This work was funded by Dimerix using data generated in the Nephrotic rsonal use only Syndrome Study Network (NEPTUNE). NEPTUNE is alumni of the Rare Diseases Clinical Research Network (RDCRN), which was funded by the National Institutes of Health (NIH) and led by the National Cente
Slide 17: Questions
rsonal use only Questions